IN THE MAZE OF MULTIPLE MYELOMA,

BCMA-DIRECTED BsAbs MAY PROVIDE A NEW WAY FORWARD^1,2

Select a path to learn more:

MM
BCMA
BsAbs

MM is considered an incurable disease with inevitable relapse, leaving no clear way forward.^3-6 Learn more about the ongoing unmet need in this disease

BCMA is a universally present and overexpressed tumor-associated antigen in MM.^1-3 Discover what makes it a promising immunotherapeutic target

In MM, BCMA-directed BsAbs have the potential to function as tumor-recognizing immune enhancers.^1-3,7-9 See how they may provide a new way forward

BCMA=B-cell maturation antigen; BsAbs=bispecific antibodies; MM=multiple myeloma.

KEEP SEEKING A NEW WAY FORWARD. NEXT: A COMPLEX DISEASE

References: 1. Caraccio C, Krishna S, Phillips DJ, Schürch CM. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Front Immunol. 2020;11:501. doi:10.3389/fimmu.2020.00501 2. Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and targeted approaches in multiple myeloma. Immunotargets Ther. 2020;9:201-215. doi:10.2147/ITT.S240886 3. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985-1005. doi.org/10.1038/s41375-020-0734-z 4. Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies, and beyond. Leukemia. 2018;32:252-262. doi:10.1038/leu.2017.329 5. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94. doi:10.1038/s41408-020-00359-2 6. Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1-7. doi.org/10.1016/j.clml.2019.09.621 7. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137-1146. doi:10.1172/JCI31405 8. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563-579. doi:10.1111/j.1365-2141.2007.06705.x 9. Zhou X, Einsele H, Danhof S. Bispecific antibodies: a new era of treatment for multiple myeloma. J Clin Med. 2020;9:2166. doi:10.3390/jcm9072166

IN THE MAZE OF MULTIPLE MYELOMA,

BCMA-DIRECTED BsAbs MAY PROVIDE A NEW WAY FORWARD1,2

MM is considered an incurable disease with inevitable relapse, leaving no clear way forward.3-6 Learn more about the ongoing unmet need in this disease

BCMA is a universally present and overexpressed tumor-associated antigen in MM.1-3 Discover what makes it a promising immunotherapeutic target

In MM, BCMA-directed BsAbs have the potential to function as tumor-recognizing immune enhancers.1-3,7-9 See how they may provide a new way forward

BCMA-DIRECTED BsAbs MAY PROVIDE A NEW WAY FORWARD^1,2

MM is considered an incurable disease with inevitable relapse, leaving no clear way forward.^3-6 Learn more about the ongoing unmet need in this disease

BCMA is a universally present and overexpressed tumor-associated antigen in MM.^1-3 Discover what makes it a promising immunotherapeutic target

In MM, BCMA-directed BsAbs have the potential to function as tumor-recognizing immune enhancers.^1-3,7-9 See how they may provide a new way forward